De Clercq & Partners proudly contributes in new Advanced Master in Biotech & MedTech Ventures
01 April 2022
A new Advanced Master in Biotech & MedTech Ventures was launched by the Solvay Brussels School of Economics and Management in collaboration with the ULB I3h Institute. The program addresses the thriving Belgian and European life sciences’ need for young entrepreneurial talent capable of taking on C-level management positions in early-stage Biotech and MedTech companies. De Clercq & Partners is honored and proud to contribute to this excellent new initiative which is designed to form the future managers in biotech and medtech.
AI Act: Brussels Has Not Banned AI - It Has Simply Asked Us to Pay Attention
Anyone who still believes that artificial intelligence operates in a legal vacuum has probably spent the past two years somewhere without Wifi. The European AI Act is now very much with us and, since 2 August 2026, a number of its rules have become directly relevant to businesses that do not build AI systems, train foundation models or employ rooms full of data scientists. They simply use AI. In other words: almost everyone.
Anne-Lore Bex and Filip Van Lysebetten qualify as European Patent Attorneys
De Clercq & Partners is delighted to announce that Anne-lore Bex and Filip Van Lysebetten have successfully passed the European Qualifying Examination (EQE) and are now officially qualified as European Patent Attorneys.
Passing the EQE is a significant professional achievement, requiring extensive technical expertise, legal knowledge and years of dedicated preparation. As European Patent Attorneys, Anne-Lore and Filip are qualified to represent clients before the European Patent Office (EPO), providing strategic advice and guidance throughout the European patent process.
Ann De Clercq recognised in Managing IP's Top 250 Women in IP 2026
De Clercq & Partners is proud to announce that our founding partner, Dr. Ann De Clercq, has once again been recognised in Managing IP's Top 250 Women in IP 2026.
